Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor‐α and melphalan for limb‐threatening soft tissue sarcoma
暂无分享,去创建一个
[1] A. Eggermont,et al. Isolated limb perfusion with tumor necrosis factor and melphalan for nonresectable Stewart-Treves lymphangiosarcoma , 2002, Annals of Surgical Oncology.
[2] M. Ballo,et al. Preoperative chemoradiation treatment strategies for localized sarcoma , 2007, Annals of Surgical Oncology.
[3] M. Ross,et al. A prospective evaluation of isolated limb perfusion with doxorubicin in patients with unresectable extremity sarcomas , 2004, Annals of Surgical Oncology.
[4] W. Molenaar,et al. Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor , 2006, Annals of Surgical Oncology.
[5] A. Eggermont,et al. Isolated Limb Perfusion With Tumor Necrosis Factor and Melphalan Prevents Amputation in Patients With Multiple Sarcomas in Arm or Leg , 2004, Annals of Surgical Oncology.
[6] P. Petrow,et al. MR imaging in the evaluation of isolated limb perfusion: a prospective study of 18 cases , 2004, Skeletal Radiology.
[7] F. van Coevorden,et al. Isolated limb perfusion with tumor necrosis factor‐α and melphalan for patients with unresectable soft tissue sarcoma of the extremities , 2003, Cancer.
[8] A. Eggermont,et al. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. , 2003, The Lancet. Oncology.
[9] G. Rosen,et al. High-Grade Extremity Soft Tissue Sarcomas: Factors Predictive of Local Recurrence and its Effect on Morbidity and Mortality , 2003, Annals of surgery.
[10] T. Delaney,et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. , 2001, International journal of radiation oncology, biology, physics.
[11] A. Eggermont,et al. Fifty Tumor Necrosis Factor–Based Isolated Limb Perfusions for Limb Salvage in Patients Older Than 75 Years With Limb-Threatening Soft Tissue Sarcomas and Other Extremity Tumors , 2003, Annals of surgical oncology.
[12] K. Hess,et al. Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas , 2002, Cancer.
[13] A. Davis,et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial , 2002, The Lancet.
[14] A. Stojadinovic,et al. Amputation for Recurrent Soft Tissue Sarcoma of the Extremity: Indications and Outcome , 2001, Annals of Surgical Oncology.
[15] J W Oosterhuis,et al. A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. , 2001, European journal of cancer.
[16] R. Mirimanoff,et al. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. , 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[17] A. Eggermont,et al. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion , 2000, British Journal of Cancer.
[18] A. Eggermont,et al. TNF- α augments intratumoural concentrations of doxorubicin in TNF- α -based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects , 2000, British Journal of Cancer.
[19] Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults. , 2000, The Cochrane database of systematic reviews.
[20] A. Eggermont,et al. Systemic Toxicity and Cytokine/Acute Phase Protein Levels in Patients After Isolated Limb Perfusion With Tumor Necrosis Factor-a Complicated by High Leakage , 2000, Annals of Surgical Oncology.
[21] D. Driscoll,et al. Treatment and local control of primary extremity soft tissue sarcomas , 1999, Journal of surgical oncology.
[22] O. Merimsky,et al. Isolated Limb Perfusion With High-Dose Tumor Necrosis Factor α and Melphalan for Kaposi Sarcoma , 1999 .
[23] O. Merimsky,et al. Isolated limb perfusion with high-dose tumor necrosis factor alpha and melphalan for Kaposi sarcoma. , 1999, Archives of surgery.
[24] R. A. MSc,et al. Modified Staging System for Extremity Soft Tissue Sarcomas , 1999, Annals of Surgical Oncology.
[25] M. Inbar,et al. High dose tumor necrosis factor‐α and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation , 1997, Cancer.
[26] M. Heslin,et al. Association of local recurrence with subsequent survival in extremity soft tissue sarcoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] C. Wiltschke,et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] P. Schlag,et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. , 1996, Annals of surgery.
[29] A. Eggermont,et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] D H Leung,et al. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] E. Casper,et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] D. Fraker,et al. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] A. Eggermont,et al. Effects of recombinant tumour necrosis factor (rTNF‐α) in cancer. Observations on the acute phase protein reaction and immunoglobulin synthesis after high dose recombinant TNF‐α administration in isolated limb perfusions in cancer patients , 1993, European journal of clinical investigation.
[34] E. Casper,et al. Comparison of Amputation With Limb‐sparing Operations for Adult Soft Tissue Sarcoma of the Extremity , 1992, Annals of surgery.
[35] J. Klaase,et al. Relation between calculated melphalan peak concentrations and toxicity in regional isolated perfusion for melanoma , 1992 .
[36] A. Eggermont,et al. Application of hyperthermia in regional isolated perfusion for melanoma of the limbs , 1992 .
[37] N. Renard,et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] E. Casper,et al. The role of multimodality therapy in soft-tissue sarcoma. , 1991, Annals of surgery.
[39] B. Kroon,et al. Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities , 1989, Cancer.
[40] W. Molenaar,et al. Results of isolated regional perfusion in the treatment of malignant soft tissue tumors of the extremities , 1987, Cancer.
[41] S. Rosenberg,et al. High‐grade soft tissue sarcomas of the extremities , 1986, Cancer.
[42] J. Coindre,et al. Soft‐tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system , 1984, International journal of cancer.
[43] E. V. van Slooten,et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. , 1982, European journal of cancer & clinical oncology.
[44] J. Tepper,et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. , 1982, Annals of surgery.
[45] B Sundell,et al. Soft-tissue sarcomas. , 1979, British medical journal.
[46] I. Hutton,et al. Chemotherapy of sarcomas of the limbs by regional perfusion. , 1977, Annals of surgery.
[47] R. F. Ryan,et al. Chemotherapy of Cancer: Regional Perfusion Utilizing an Extracorporeal Circuit , 1958, Annals of surgery.